个人简介：

朱建飞，男，1986年07月18日出生，博士学历，博士学位，副主任医师，陕西中医药大学硕士研究生指导教师。现任陕西省人民医院胸外科副主任，兼任中国抗癌协会纵隔肿瘤整合康复医学会委员，西安市研究型医院学会胸外科专业委员会常委，陕西省日间医疗学会青年分会常委，西安市胸外科学会委员。

学习工作经历：

2010年7月本科毕业于第四军医大学，硕士毕业于中山大学，博士毕业于空军军医大学，毕业后长期在陕西省人民医院胸外科工作，主要从事胸部疾病的以外科为中心的综合治疗10年，作为术者，参与国际上首例Y型钛板联合髂骨移植重建胸骨肿瘤切除后的胸壁缺损手术以及世界首例肋骨悬吊治疗重度气管软化症患者的救治等多项全球高尖端胸外科手术。

研究方向：

胸部肿瘤的基础、转化研究及外科治疗

科研课题：

（1）陕西省自然科学基金委员会，面上项目，2024JC-YBMS-738，E2F1转录激活CKS1B促进ⅢA-N2期肺腺癌恶性进展的作用机制研究，2024.01-2025.12, 5.0万元，在研，主持；

（2）西安交通大学，基本科研业务费“自由探索教师类项目”，xzy012023125, 肺腺癌起源的分子机制研究：Clara细胞和AT2细胞平行起源学说，2023.01-2025.12，10.0万元，在研，主持；

（3）陕西省人民医院，菁英人才项目，2021.JY-20，FOXP3阳性肺腺癌招募Treg细胞促进肺腺癌浸润转移的分子机制研究，2022.01-2023.12，10.0万元，在研，主持；

（4）陕西省人民医院，科技发展孵化基金，2022YJY-26，“E2F1-CKS1B”轴在pN2期肺腺癌分子分型中的作用机制研究，2023.01-2024.12，1.5万元，在研，主持；

（5）吴阶平基金会，卓越外科基金，320.6750.17527, 应用核函数建立EGFR突变阳性的非小细胞肺癌术后的预后预测模型，2017.01-2019.12, 4.0万元，结题，主持。

发表论文：

1.Zhu J^#, Fan Y^#, Xiong Y^#, Wang W^#, Chen J, Xia Y, Lei J*, Gong L*, Sun S*, Jiang T*. Delineating the Dynamic Evolution From Preneoplasia to Invasive Lung Adenocarcinoma by Integrating Single-Cell RNA Sequencing and Spatial Transcriptomics[J]. Exp Mol Med, 2022, 54(11):2060-2076. (IF：12.80)

2.Ma Y^#, Li W^#, Li Z, Chen J, Wang H, Jiang T*,Zhu J*. Immunophenotyping of pulmonary sarcomatoid carcinoma[J]. Frontiers in Immunology, 2022; 13:976739. (IF: 8.786)

3.Xia J^#, Zhang J^#, Xiong Y, Zhao J, Zhou Y, Jiang T*,Zhu J*. Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer. Expert Review of Molecular Diagnostics. (IF:5.1)

4.Zhu J^#, Wang W^#, Xiong Y^#, Xu S, Chen J, Wen M, Zhao J, Lei J*, Jiang T*. Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma[J]. Cancer Medicine, 2022. (IF: 4.711)

5.Zhu J^#, Wang W^#, Ma Y^#, Zhao J*, Xiong Y*. Development and validation of a gene-based classification model for pN2 lung  adenocarcinoma. Transl Lung Cancer Res. 2023 2023-03-31;12(3):494-509. (IF：4.0)

6.Zhu J^#, Xu S^#, Gao W^#, Feng J*, Zhao G*. Honokiol induces endoplasmic reticulum stress-mediated apoptosis in human lung cancer cells[J]. Life Sci, 2019, 221: 204-211. (IF: 3.647)

7.Ma Y^#, Chen J, Yao X, Li Z, Li W, Wang H,Zhu J*. Patterns and prognostic predictive value of perineural invasion in esophageal squamous cell carcinoma[J]. BMC Cancer,2022,22(1):1287. (IF：3.8)

8.Ma Y^#, Yao X^#, Li Z^#, Chen J, Li W, Wang H, Zhang L,Zhu J*. The role of vascular invasion and lymphatic invasion in predicting recurrent thoracic oesophageal squamous cell carcinoma[J]. World J Surg Oncol, 2022,20(1):12. (IF: 3.2)

9.Zhu J^#, Zhang Q^#, Jia C, Xu S, Lei J, Chen J, Xia Y, Wang W, Wang X, Wen M, Wang H, Zhang Z, Wang W*, Zhao J*, Jiang T*. Challenges Caused by Imported Cases Abroad for the Prevention and Control of COVID-19 in China[J]. Front Med (Lausanne), 2021,8:573726.（IF：5.091）

10.Zhu J^#, Wang W^#, Xu S^#, Jia C, Zhang Q, Xia Y, Wang W, Wen M, Wang X, Wang H, Zhang Z, Cai L*, Zhang L*, Jiang T*. Evaluation of the Effect of Lymph Node Status on the Survival of Non-Small Cell Lung Cancer Patients With Brain Metastases: Applications of a Novel Grade Prognostic Assessment Score Model Involving N Stage[J]. Front Oncol, 2020,10:563700. （IF：6.244）

11.Zhu J^#, Zhang Q^#, Jia C^#, Wang W^#, Chen J, Xia Y, Wang W, Wang X, Wen M, Wang H, Zhang Z, Xu S*, Zhao J*, Jiang T*. Epidemiological Characteristics and Clinical Outcomes of Coronavirus Disease Patients in Northwest China: High-Volume Research From Low Population Density Regions[J]. Front Med (Lausanne), 2020,7:564250. （IF：5.091）

12.Zhu J^#, Xu S^#, Gao W^#, Feng J*, Zhao G*. Honokiol induces endoplasmic reticulum stress-mediated apoptosis in human lung cancer cells[J]. Life Sci, 2019, 221: 204-211. (IF: 3.647)

13.Zhu J^#, Feng X^#, Zhang X, Wen Y S, Lin P, Cai L, Zhang L*. Time distribution of recurrence risk of oesophageal squamous cell carcinoma with complete resection (R0) in a Chinese population[J]. Eur J Cardiothorac Surg, 2015,48(6):899-905. （IF：2.804）

14.Zhu J^#, Cai L^#, Zhang X, Wen Y, Su X, Rong T, Zhang L*. High plasma fibrinogen concentration and platelet count unfavorably impact survival in non-small cell lung cancer patients with brain metastases[J]. Chin J Cancer, 2014,33(2):96-104. （IF：3.822）

15.Zhu J^#, Cai L^#, Yang H, Wen Y, Wang J, Rong T, Shao J, Zhang L*. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma[J]. Thorac Cancer, 2014,5(5):411-416. （IF：2.569）

16.Zhu J^#, Feng X^#, Zhang X, Wen Y, Lin P, Rong T, Cai L, Zhang L*. Time-varying pattern of postoperative recurrence risk of early-stage (T1a-T2bN0M0) non-small cell lung cancer (NSCLC): results of a single-center study of 994 Chinese patients[J]. PLoS One, 2014,9(9):e106668. （IF：2.97）

17.Zhu J^#, Ni Y^#, Lu Q^#, Li X, Wang W*, Wang H*. Benign esophago-pulmonary fistula complicating achalasia: case report and literature review[J]. J Thorac Dis, 2015,7(4):E92-E96. （IF：1.783）

18.Zhu J^#, Li Z, Chen J, Li W, Wang H, Jiang T, Ma Y*. A comprehensive bioinformatics analysis of FOXP3 in non-small cell lung cancer[J]. Medicine,2022,50.101.e32102. (IF：1.6)

19.Lei J^#,Zhu J^#, Hui B^#, Jia C, Yan X, Jiang T*, Wang X*. Circ-HSP90A expedites cell growth, stemness, and immune evasion in non-small cell lung cancer by regulating STAT3 signaling and PD-1/PD-L1 checkpoint. Cancer Immunology Immunotherapy. 2022. (IF: 5.8)

20.Ma S^#,Zhu J^#, Xue M^#, Shen Y, Xiong Y, Zheng K, Tang X, Wang L, Ni Y, Jiang T*, Zhao J*. Early postoperative endoscopy for predicting anastomotic leakage after minimally  invasive esophagectomy: A large-volume retrospective study. Surgery, 2024;175:1305-1311. (IF: 3.2)

21.Zhang Q^#,Zhu J^#, Jia C^#, Xu S*, Jiang T*, Wang S*. Epidemiology and Clinical Outcomes of COVID-19 Patients in Northwestern China Who Had a History of Exposure in Wuhan City: Departure Time-Originated Pinpoint Surveillance[J]. Front Med (Lausanne), 2021,8:582299. （IF：5.091）

22.Cai L^#,Zhu J^#, Zhang X, Lin S, Su X, Lin P, Chen K, Zhang L*. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer[J]. J Neurooncol, 2014,120(2):423-430. （IF：3.06）

23.Xu S^#,Zhu J^#, Zhao G*, Li S*. Tracheal suspension with autogenous rib cartilage in a patient with severe tracheomalacia[J]. J Cardiothorac Surg, 2019,14(1):21. （IF：1.470）

24.Chen J^#,Zhu J^#, Zhang Y, Wang W, Xia Y, Zhao J*, Jiang T*. Efficacy of albumin-bound paclitaxel combined with nedaplatin in neoadjuvant  therapy for esophageal squamous cell carcinoma: A single-center retrospective  observational study. Medicine (Baltimore). 20232023-03-03;102(9):e33157. (IF：1.6)

25.Zhu J^#, Yuan J, Dou Y, Tian W, Li S, Wang H, Li Z*. Is EGFR gene mutation testing necessary in smokers with non-small cell lung cancer? Oncology and Translational Medicine 2017;3:156-159.

26.Xu S^#, Zhu J^#, Dou Y^#, Tian W, Dai Y, Luo X, Wang H*. Analysis of long-term outcomes and application of the tumor regression grading system in the therapeutic assessment of resectable limited-disease small cell lung cancer. Oncology and Translational Medicine 2016;2:227-233.

会议特邀学术报告：

（1）Zhu J^#, Ma Y, Wang H*. Diversity of perineural invasion and their predictive role in prognosis of esophageal squamous cell carcinoma. 18th ISDE World Congress for Esophageal Diseases, Tokyo, Japan, Oral Presentation, 2022.09.26-2022.09.28.

（2）Zhu J^#, Wang W, Ma Y, Xiong Y*. MA06.07: Molecular Typing of pN2 Lung Adenocarcinoma: Retrospective Study Based on Transcriptome Sequencing. IASLC 2022 World Conference on Lung Cancer, Vienna, Austria , Mini-oral presentation, 2022.08.06-2022.08.09

著作教材：

无。

授权专利：

朱建飞，李曙东，王宏涛，一种胸外患者术后多功能定位器，2022.06.14，中国，ZL202210664059.5。

获奖情况：

全国教育系统教育教学成果大赛，《肺小结节的诊疗规范》，一等奖，2022年。

联系方式：

邮箱：zhujianfei718@163.com；